Pangenomic Health Inc.
NARA
CNSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 134.07% | 122.29% | 438.85% | -63.27% | -70.45% |
| Gross Profit | -134.07% | -122.29% | -438.85% | 63.27% | 70.45% |
| SG&A Expenses | 70.86% | 52.90% | -72.53% | -41.65% | -74.84% |
| Depreciation & Amortization | -95.65% | -95.65% | -95.65% | -34.78% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 78.78% | 92.21% | -2.06% | -51.18% | -74.34% |
| Operating Income | -78.78% | -92.21% | 2.06% | 51.18% | 74.34% |
| Income Before Tax | 84.56% | -71.97% | -48.60% | 51.46% | -159.56% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 84.56% | -71.97% | -48.60% | 51.46% | -159.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 84.56% | -71.97% | -48.60% | 51.46% | -159.56% |
| EBIT | -78.78% | -92.21% | 2.06% | 51.18% | 74.34% |
| EBITDA | -81.23% | -95.29% | 1.49% | 51.35% | 74.61% |
| EPS Basic | 93.80% | 50.06% | 43.37% | 84.96% | 7.85% |
| Normalized Basic EPS | 39.72% | 50.10% | 61.61% | 84.55% | 90.50% |
| EPS Diluted | 93.80% | 50.06% | 43.37% | 84.96% | 7.85% |
| Normalized Diluted EPS | 39.72% | 50.10% | 61.61% | 84.55% | 90.50% |
| Average Basic Shares Outstanding | 149.00% | 244.55% | 162.36% | 222.15% | 181.71% |
| Average Diluted Shares Outstanding | 149.00% | 244.55% | 162.36% | 222.15% | 181.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |